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Abstract
Down syndrome (DS, trisomy 21) is the most common chromosomal disorder and the leading genetic cause of intellectual
disability in humans. In DS, triplication of chromosome 21 invariably includes the APP gene (21q21) encoding the
Alzheimer’s disease (AD) amyloid precursor protein (APP). Triplication of the APP gene accelerates APP expression leading to
cerebral accumulation of APP-derived amyloid-b peptides (Ab), early-onset AD neuropathology, and age-dependent
cognitive sequelae. The DS phenotype complex also includes distinctive early-onset cerulean cataracts of unknown etiology.
Previously, we reported increased Ab accumulation, co-localizing amyloid pathology, and disease-linked supranuclear
cataracts in the ocular lenses of subjects with AD. Here, we investigate the hypothesis that related AD-linked Ab pathology
underlies the distinctive lens phenotype associated with DS. Ophthalmological examinations of DS subjects were correlated
with phenotypic, histochemical, and biochemical analyses of lenses obtained from DS, AD, and normal control subjects.
Evaluation of DS lenses revealed a characteristic pattern of supranuclear opacification accompanied by accelerated
supranuclear Ab accumulation, co-localizing amyloid pathology, and fiber cell cytoplasmic Ab aggregates (,5 to 50 nm)
identical to the lens pathology identified in AD. Peptide sequencing, immunoblot analysis, and ELISA confirmed the identity
and increased accumulation of Ab in DS lenses. Incubation of synthetic Ab with human lens protein promoted protein
aggregation, amyloid formation, and light scattering that recapitulated the molecular pathology and clinical features
observed in DS lenses. These results establish the genetic etiology of the distinctive lens phenotype in DS and identify the
molecular origin and pathogenic mechanism by which lens pathology is expressed in this common chromosomal disorder.
Moreover, these findings confirm increased Ab accumulation as a key pathogenic determinant linking lens and brain
pathology in both DS and AD.
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Introduction
Down syndrome (DS, [1]) is the leading genetic cause of
intellectual disability and the most common chromosomal disorder
compatible with human survival [2,3,4,5]. DS affects approxi-
mately 1 in 700 live births and an estimated 220,000 newborns
each year [6]. In the majority of cases, the disorder arises from
sporadic non-disjunction of chromosome 21 (HSA21) and
triplication of the entire chromosome [7,8,9], or infrequently,
from partial aneuploidy due to unbalanced chromosomal
translocation [10,11,12,13]. In most cases, DS aneuploidy disrupts
gene-dose equilibrium in all somatic cells, whereas a minority of
cases demonstrates mosaicism [14]. Chromosomal triplication
invariably includes the APP gene (21q21) that encodes the amyloid
precursor protein, APP [15,16]. Endoproteolytic cleavage of APP
yields the pathogenic amyloid-b peptides (Ab) that progressively
accumulate in the brain as the diffuse and neuritic plaques of
Alzheimer’s disease (AD). In DS, cerebral Ab accumulation is
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neuropathology and age-dependent neurocognitive sequelae
[18,19].
Lens abnormalities in subjects with clinical features of DS were
first reported over a century ago [20,21] followed by numerous
confirmatory reports since [20,22,23,24]. The distinctive DS lens
phenotype clinically manifests as cerulean ‘‘blue dot’’ opacities that
often emerge in the first decade of life, and in some cases, may be
evident at birth [22,25,26,27]. DS cataracts typically localize to
the supranuclear region and are histologically characterized by
granular material of uncertain composition [20,24,25]. The
molecular origin and pathogenic mechanisms by which the DS
aneuploidy is expressed as a distinctive age-dependent lens
phenotype are unknown.
We previously reported disease-linked supranuclear cataracts
that correlate with pathogenic Ab accumulation, classical amyloid
pathology, and co-localizing pathology in lenses obtained from
subjects with Alzheimer’s disease (AD) but not in those with other
neurodegenerative disorders nor in normal aged controls [28]. In
AD lenses, Ab accumulates as electron-dense cytosolic aggregates
(longest axial dimension, ,5n m t o ,200 nm) that distribute
heterogeneously within the cytoplasm of supranuclear and deep
cortical lens fiber cells. AD-linked Ab aggregates in the lens qualify
as Raleigh scattering centers that clinically manifest as supranu-
clear opacities that ultimately progress to frank cataracts. These
AD-linked supranuclear cataracts are phenotypically, anatomical-
ly, ultrastructurally, and biochemically distinguishable from
common age-related nuclear cataracts. Given the association
between Ab amyloid lens pathology in AD [28], we hypothesized
that subjects with DS would also demonstrate age-related Ab
amyloid pathology in the lens. The aim of the present study was to
test the hypothesis that DS-linked lens pathology reflects
accelerated Ab accumulation and co-localizing amyloid pathology
that clinically manifests as the characteristic supranuclear cataract
phenotype associated with this common chromosomal disorder.
Methods
Subjects and Specimens
Lens specimens were obtained from the following sources: (i)
subjects with DS requiring cataract surgery (n=3 males: 36, 46, and
47 years of age) at the Massachusetts Eye and Ear Infirmary; (ii)
postmortem specimens from donors with DS (n=12 total; n=9
m a l e s :2t o6 9y e a r so fa g e ;n=3f e m a l e s :4 2 ,4 7 ,a n d6 1y e a r so fa g e )
and normal controls (n=34 total; n=20 males: 7 months to 88 years
of age; n=14 females: 2 to 82 years of age) procured through national
tissue networks (National Disease Registry Interchange, Philadelphia;
PA; Florida Lion’s Eye Bank, Miami, FL; Sun Health Research
Institute, Sun City, AZ); and (iii) archival lens specimens generously
provided by Dr. Richard Robb, Children’s Hospital, Harvard
Medical School, Boston, MA (DS, n=4 total; n=3 males: 1 day, 3
weeks, and 22 years of age; n=1 female: 7 months of age. Normal
controls, n=3 total; n=2 males, 1 day and 21 years of age; n=2
females, 2 days and 4 months of age). An earlier histochemical
analysis of lenses from this archival collection was reported in 1978
[24]. Postmortem brain specimens (superior temporal cortex) were
obtained from the Massachusetts Alzheimer’s Disease Research
Center Brain Bank (Massachusetts General Hospital, Boston, MA,
USA), and included the following donor groups: AD (CERAD
criteria) n=3 total; n=1 male: 86 years of age; n=2 females: 76 and
81 years of age); DS (karyotype confirmed) n=4 total; n=4 males:
56, 57, 58, and 60 years of age); normal controls (n=3 total; n=1
male: 86 years of age; n=2 females: 72 and 88 years of age). Clinical
information regarding cytogenetic microanalysis and chromosomal
subtyping was not available. Lenses obtained from intact postmortem
eyes were the only specimens used for biochemical analysis. All lenses
obtained from intact, non-traumatic globes were included in the
study and assigned to cohorts based on available clinical information.
No other selection criteria were applied.
Ethical review and permission to conduct this investigation were
approved by Harvard Medical School, Brigham and Women’s
Hospital, Massachusetts Eye and Ear Infirmary, and Children’s
Hospital Boston. This study conforms to applicable regulatory
guidelines at Harvard Medical School and principles of human
research subject protection in the Declaration of Helsinki. Patients
were informed, consent forms signed, and patient samples
collected and signed in accordance with an approved IRB
protocol (02-08-053X) at the Massachusetts Eye and Ear
Infirmary, Boston, MA, USA.
Slit Lamp Biomicroscopy
Clinical ophthalmological examinations included slit lamp
stereophotomicroscopy and microvideography following routine
pupillary dilation. In three DS cases (n=3 males: 36, 46, and 47
years of age), slit lamp photomicrographs were obtained in
conjunction with cataract surgery. Patients were informed and
signed consent forms in accordance with an approved IRB
protocol at the Massachusetts Eye and Ear Infirmary, Boston, MA,
USA. Stereophotomicroscopic analysis of dissected intact human
lenses was performed on postmortem specimens obtained from
enucleated eyes procured through national tissue bank resources
(National Disease Registry Interchange, Philadelphia; PA; Florida
Lion’s Eye Bank, Miami, FL). Harvested lenses were bathed in
buffered artificial aqueous humor (295 mOsm, pH 7.20) at 37uC,
visualized with a custom-adapted surgical slit lamp stereophoto-
microscope (Carl Zeiss, Thornwood, NY) equipped with a stereo
beamsplitter (Urban Engineering, Burbank, CA) and side-arm
digital camera assembly (Nikon, Melville, NY).
Histopathology, Immunohistochemistry, Light and
Electron Microscopy
A portion of the present study included re-analysis of lens
specimens from an archival collection generously provided by co-
author Richard Robb, M.D., Department of Ophthalmology,
Children’s Hospital Boston, Harvard Medical School, Boston,
MA. Paraffin-embedded specimens in this collection date back to
the 1960’s and have been previously described [24]. Original
paraffin blocks in this archival collection were highly friable and
required re-embedding in fresh paraffin prior to histological
processing. For all histological studies, routine tissue sections
(8 mm) were obtained by microtomy, immunostained with Ab
monoclonal antibody 6E10 directed against Ab3–8 or 4G8 directed
against Ab18–22 (generously provided by Joseph Bertelsen, Signet
Laboratories, Covance, Dedham, MA), and processed by
conventional immunohistochemistry using a commercial kit
(Vector Laboratories, Burlingame, CA) according to the manu-
facturer’s instructions. Bennhold’s modified Congo red staining
method [29] was used for amyloid histopathology. Brightfield and
cross-polarization photomicroscopy were conducted using a Nikon
Eclipse E600 upright microscope (Nikon USA, Melville, NY)
equipped with a Spot Slider RT digital CCD photomicroscope
camera and proprietary image acquisition software (Diagnostic
Instruments, Sterling Heights, MI).
Immunogold Electron Microscopy
Immunogold electron microscopy (IEM) was conducted as
previously described using ultra-thin cryosections without plastic
Ab in Lens in Down Syndrome
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carbon-coated grid, blocked for 10 min in 1% BSA, immunola-
beled with the first detection antibody using anti-Ab monoclonal
antibody 4G8 (Signet Laboratories, Covance, Dedham, MA), then
incubated with rabbit anti-mouse bridging antibody followed by
incubation with 10 nm immunogold-conjugated Protein A (Jan
Slot, Utrecht, Netherlands). Grids were fixed briefly in 1%
glutaraldehyde, floated on 4 drops of 0.02M glycine/PBS to
quench free aldehyde groups, then immunolabeled with the
second detection antibody using a rabbit anti-aB-crystallin
polyclonal antibody (Dr. Jack Liang, Brigham & Women’s
Hospital, Boston, MA, USA) or normal rabbit serum control.
Specimens were then exposed to 15 nm immunogold-conjugated
Protein A (Jan Slot, Utrecht, Netherlands), negatively stained with
uranyl acetate, and examined on a JEOL 1200EX transmission
electron microscope at the Electron Microscope Facility, Harvard
Medical School. All immunohistochemical analyses included
specificity controls in which identically processed specimens were
incubated with detection antibody that was immunodepleted by
pre-absorption with synthetic antigen (human Ab42, Keck
Laboratory, Yale University, New Haven, CT) as previously
described[28].
Tryptic Digest Tandem Mass Spectrometry Protein
Sequencing
Lens specimens were homogenized in 70% formic acid, ultra-
centrifuged at 100,0006g for 1 h at 4uC, and fractions separately
retained for biochemical analysis. Supernatant was concentrated
by nitrogen stream, neutralized with NaOH, and diluted 50-fold in
TBS containing 10 mg anti-Ab monoclonal antibody 6E10 (Signet
Laboratories, Covance, Dedham, MA). Immunocomplexes were
precipitated with magnetic beads covalently coupled to sheep anti-
mouse antibody (Invitrogen, Carlsbad, CA), separated from
unbound material by exposure to a magnetic field, and released
by acidification in 100 mM glycine at pH 3. Samples were then
subjected to reverse phase HPLC on a ZORBAX SB-C8 column
(Agilent, Santa Clara, CA) and eluted under isocratic conditions
(0.1% TFA; 30.5% acetonitrile) at 1 ml/min at 80uC. Elution
times were determined by comparison to chromatographic profiles
of synthetic human Ab (Keck Laboratory, Yale University, New
Haven, CT). Isolated fractions were dried by vacuum centrifuga-
tion, digested with trypsin, and fractionated by reverse phase
HPLC. Post-digest eluates were subjected to electrospray ioniza-
tion and ESI-tandem MS/MS LCQ-DECA ion-trap mass
spectrometry (ThermoFinnigan, San Jose, CA) at the Taplin Mass
Spectrometry Facility, Harvard Medical School. Peptide sequenc-
es were identified by computer-assisted search program (Sequest,
Thermo Fisher Scientific, Waltham, MA).
Ab Fluoro-ELISA and Ab Immunoblotting
Analytical quantification of human Ab40 and human Ab42 was
accomplished using two commercially available human Ab specific
ELISA kits (BetaMark, Covance, Dedham, MA; BioSource,
Invitrogen, San Diego, CA). For experiments utilizing SDS
extracted tissue, we used a commercially available human Ab
ELISA kit (BetaMark, Covance, Dedham, MA) that is resistant to
interference from detergent. This ELISA assay system is
compatible with tissue extracts containing SDS with minimal loss
in sensitivity. Samples containing SDS were diluted to a final
detergent concentration of less than 0.1%. For experiments
utilizing formic acid extracted tissue, we used a second
commercially available Ab ELISA kit (BioSource, Invitrogen,
San Diego, CA). For immunoblotting analysis, lens subcellular
fractions were normalized for protein concentration and analyzed
as previously described [28]. Blots were probed with human Ab-
specific monoclonal antibody WO2 (Genetics Company, Zurich,
Switzerland) directed against human Ab4–10 or monoclonal
antibody 6E10 (Signet Laboratories, Covance, Dedham, MA)
directed against human Ab3–8.
Quasi-Elastic Light Scattering Analysis of Human Lens
Protein Suspensions
Quasi-elastic light scattering (QLS) experiments were conducted
using a custom laboratory instrument (Neuroptix Corporation,
Acton, MA) that delivers linearly polarized continuous wave near-
infrared laser light (l=780 nm; focused beam diameter, 30–
35 mm; power output=0.3 mW). The instrument incorporates a
rigidly positioned pinhole mirror (aperture diameter=100 mm) for
selective detection of backscattered photons at a fixed scattering
angle (h=120 degrees). Signal detection and analysis of backscat-
tered light intensity was accomplished with an avalanche
photodiode, integrated 256-channel multi-tau digital autocorre-
lator (t=480 ns), and custom software analysis package. Analyses
involving aqueous suspensions of water-soluble lens proteins were
conducted in cylindrical optical glass specimen vials positioned in a
rigid holder mounted to the instrument. Three series of five
independent measurements (each 1.3 seconds in duration) were
performed for a total of fifteen measurements comprising each
averaged test point. To investigate the interaction of Ab peptides
with other cytosolic lens proteins, a membrane-free water-soluble
protein extract was prepared from freshly dissected human lenses
obtained from postmortem donor eyes (National Disease Registry
Interchange, Philadelphia; PA; Florida Lion’s Eye Bank, Miami,
FL). Dissected lenses were mechanically homogenized, ultracen-
trifuged at 100,0006g for 1 h at 4uC, and diluted to 1 mg/ml in
phosphate buffered saline, pH 7.20. This aqueous lens protein
extract is predominantly composed of water-soluble proteins in the
cytoplasm of lens fiber cells. Purified synthetic human Ab42 or
Ab40 (Keck Laboratories, Yale University, New Haven, CT) was
added to freshly prepared human lens protein extract and
incubated in siliconized Eppendorf tubes in a humidified 37uC
5% CO2-balanced tissue culture chamber prior to light scattering
analysis. All samples were incubated in the dark to reduce
photodynamic effects. For microscopic visualization, aliquots of
the incubated samples were placed on a microscope slide as wet-
mount preparations and visualized by conventional photomicros-
copy under brightfield and cross-polarized illumination. Immuno-
gold electron microscopic analysis of incubated material was
conducted as detailed above.
Results
Supranuclear Cataract Pathology in Down Syndrome
Lenses
Slit lamp examination of subjects with karyotype-confirmed DS
revealed classical cerulean ‘‘blue dot’’ cataracts (Fig 1A) with a
characteristic subequatorial supranuclear distribution (Fig. 1B,C)
and corresponding increased localized static light scattering
(Fig. 1D). The anatomical localization of the diffuse opacities
observed by indirect ophthalmoscopy (Fig. 1A) correspond to a
distinctly annular supranuclear distribution as revealed by retro-
illumination (Fig. 1B,C) and confirmed by scattering densitometry
(Fig. 1D) of the same lens. The lens from a 2-year-old male with
DS demonstrated grossly normal transparency without evidence of
clinically detectable lenticular pathology (Fig. 1E). By contrast, the
DS supranuclear cataract phenotype was identified in all adult DS
patients clinically examined and in all postmortem lens specimens
from adult DS donors. Lenses from mature DS subjects
Ab in Lens in Down Syndrome
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ogy (Fig. 1E-H) that was phenotypically indistinguishable from
that previously reported in late-onset sporadic AD (Fig. 1F-H)
[28].
A representative stereo image of a lens from a 64-year-old male
with DS (Fig. 2A) illustrates an advanced circumferential
supranuclear cataract characteristic of the DS phenotype. The
phenotypic features of this distinctive cataract phenotype are
demonstrated in the same lens observed by slit lamp photomi-
croscopy (Fig. 1H) and as a stereo image pair with intact zonule
fibers (Fig. S1). The cataract phenotype observed in DS was
strikingly similar to the mature subequatorial supranuclear
cataracts previously reported in advanced AD (Fig. 2B; [28]).
This distinctive DS-associated cataract was not present in age-
matched normal control subjects nor was this focal lens pathology
associated with global swelling, diffuse opacification, or capsular
disruption indicative of postmortem tissue injury.
Histochemical and Ultrastructural Analyses
The phenotypic correspondence of the distinctive cataracts in
DS and AD encouraged us to investigate the possibility of Ab
pathology in DS lenses. Orientation to the anatomy of the adult
human lens is shown (Fig. 3A,B) and compared to an historical
drawing (Fig. 3C) illustrating the distinctive localized supranuclear
lens pathology in a 37-year-old subject with clinical features
consistent with Down syndrome [23]. Amyloid histochemical
analysis of DS lenses in the present study demonstrated Congo red
staining (Fig. 3D) and intense apple-green birefringence (Fig. 3E)
under cross-polarized illumination, findings consistent with the
tinctorial requirements for designation as amyloid pathology
[30,31]. Amyloid histopathology was not evident in a lens from
an age- and sex-matched normal control donor (Fig. 3F) and co-
localized with lens pathology and Ab immunoreactivity as
demonstrated by specific Ab immunoreactivity in the deep
cortical, supranuclear, and anterior epithelial subregions
(Fig. 3G). Anti-Ab immunoreactivity was not detected in adjacent
control sections probed with immunodepleted detection antibody
(Fig. 3H) or in lens specimens from age- and sex-matched normal
control donors (Fig. 3I). Anti-Ab immunogold electron microscopy
revealed immunoreactive aggregates (,5–50 nm) that localized to
the cytoplasm of supranuclear fiber cells in DS lenses (Fig. 3J,K)
but was not observed in adjacent control sections probed with
Figure 1. Phenotypic expression of representative supranuclear cataracts in Down syndrome. (A-C) Representative supranuclear
cataract in a 46-year-old male with Down syndrome observed by slit lamp biomicroscopy. (A) Broad-beam illumination demonstrates numerous
cerulean coronary ‘‘blue dot’’ lens opacities. Asterisk denotes first Purkinje image (corneal specular reflection). (B) Retro-illumination reveals a
distinctive peripheral ring of opacification in the subequatorial supranuclear subregion of the lens. Red reflex is imparted by retinal reflection. Corneal
Purkinje image is evident centrally (asterisk). (C) Inverted grayscale rendering of the retro-illumination image highlights the circumferential
subequatorial supranuclear opacification (dashed circle) that characterizes the distinctive Down syndrome cataract phenotype. Corneal Purkinje
image is evident centrally (asterisk). (D) Static light scattering intensity plotted as a function of anatomical position within the lens. Axial location is
referenced to the dashed line and anatomical orientation axes represented in the inset. (E-H) Representative stereophotomicroscopic images of ex
vivo lenses from subjects with Down syndrome of indicated ages and gender. Colored dots indicate superior and inferior extent of the slit beam
ribbon defining the posterior surface of each imaged lens. White dots indicate superior and inferior extent of the light reflex on the anterior aspect of
each imaged lens. (E) Lens from a 2-year-old male with Down syndrome. Slit beam photomicroscopy demonstrates a grossly normal transparent lens.
(F) Lens from a 42-year-old female with Down syndrome. Supranuclear opacification is evident in a semicircular arc (dashes) with prominent cortical
spokes and moderate lenticular brunescence. (G) Lens from a 61-year-old female with Down syndrome. Distinctive supranuclear opacification
describes an incomplete supranuclear arc (dashes). Cortical spokes and moderate lenticular brunescence are present. (H) Lens from a 64-year-old
male with Down syndrome. Prominent circumferential opacification is present as a subequatorial supranuclear ring cataract (dashed circle). This
cataract describes an annular half torroid that follows the anteroposterior orientation of the supranuclear fiber cells enveloping the peripheral extent
of the embryonic nucleus. Cortical spokes and moderate lenticular brunescence are evident. This same lens is presented as a stereo image pair with
and without intact zonule fibers (Fig. S1 and Fig. 2, respectively). See text for details.
doi:10.1371/journal.pone.0010659.g001
Ab in Lens in Down Syndrome
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logical findings are identical to those previously described for lens
pathology in late-onset sporadic AD [28].
Identification and Biochemical Characterization of Ab in
Down Syndrome Lens
DefinitiveidentificationofhumanAbin DS lens was accomplished
by tryptic digest tandem mass spectrometry peptide sequencing.
Biochemical sequencing analysis was conducted on small molecular
weight eluates derived from HPLC fractionation of human DS lens
protein extract (Fig. 4). In positive electrospray mode, the LC-MS/
MS spectrum detected two tryptic peptide signals corresponding to
17LVFFAEDVGSNK28 and 6HDSGYEVHHQK16 that uniquely
identify human Ab. The detected fragments did not derive from the
larger amyloid precursor protein (APP) as sequencing was performed
on eluates with retention times corresponding to monomeric Ab (,4
kDa). In order to establish the tissue concentration of Ab in the lens,
we first investigated the relative efficiency of sodium dodecyl sulfate
compared to formic acid extraction performed on protein extracts
obtained from human lens homogenates (Fig. 5). Formic acid
demonstrated a far superior extraction profile relative to sodium
dodecylsulfateforbothAb1-40andAb1-42.ELISAresults(Fig.6A,B)
demonstrated elevated lens and brain tissue levels of the major
human Ab isoforms (Ab40 and Ab42)a n dt o t a lA b that were
consistently elevated in DS compared to normal controls and
comparable to the values previously reported in AD [28].
Immunoblot analysis of DS lens extract (Fig. 6C) revealed a
prominent Ab-immunoreactive band that migrated with an apparent
Figure 2. Stereo images demonstrating mature supranuclear lens pathology in Down syndrome and Alzheimer’s Disease. (A)
Characteristic circumferential supranuclear cataract in the lens of a 64-year-old male subject with Down syndrome. This distinctive cataract is evident
as an annular half-toroid band of opacification in the deep cortical and supranuclear subregions of the lens. This same lens specimen is presented as a
slit lamp biomicrocopic image (Fig. 1H) and as a stereo image pair (with intact zonule fibers, Fig. S1). This dramatic Down syndrome cataract is
phenotypically comparable to the incomplete subequatorial supranuclear cataract observed in the lens of a 76-year-old male subject with advanced
Alzheimer’s disease (B). These distinctive supranuclear cataracts are not observed in age-normal control subjects. See text for details.
doi:10.1371/journal.pone.0010659.g002
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21-year-old male subject with Down syndrome. Hematoxylin and eosin. (B) Schematic diagram identifying anatomical regions of the human lens
(adapted from Histology of the Human Eye: An Atlas and Textbook [52]). (C) Archival rendering of classical coronary cerulean ‘‘flake’’ arcuate cataracts in
a 40-year-old male with presumptive Down syndrome (from Lowe, 1949 [23]). This historical folio drawing illustrates the mature Down syndrome
supranuclear cataract phenotype with dominant subequatorial localization and anteroposterior extension. (D-F) Congo red amyloid histochemical
analysis of lenses from a 21-year-old male with Down syndrome and age-matched normal male control. (D) Congophilia in the cortex and
supranuclear subregion of the lens from a 21-year-old male with Down syndrome. (E) Intense co-localizing apple-green birefringence in the
corresponding cortical and supranuclear subregions of the same Congo red-stained Down syndrome lens imaged with cross-polarized illumination.
(F) Amyloid histochemical analysis of a lens from a 21-year-old normal control subject did not demonstrate Congophilia nor classical apple-green
birefringence under identical cross-polarized illumination. (G)A b immunoreactivity in the epithelium, deep cortex, and supranuclear regions in a lens
from a 22-year-old male with Down syndrome. Inset, magnified detail of the anterior lens (box). Cap, capsule; epi, epithelium; cor, cortex; snc,
supranucleus; nuc, nucleus. (H) Confirmation of anti-Ab antibody specificity in the same Down syndrome lens by immunodepletion of the detection
antibody with synthetic human Ab. Adjacent section of the same Down syndrome lens in Fig. 3G (I) Absence of Ab immunoreactivity in the lens of a
normal 22-year-old male control subject. (J) Anti-Ab immunogold electron microscopic analysis of lens from a 58-year-old male with Down syndrome.
Heterogeneously distributed anti-Ab immunoreactive protein aggregates of dimensions ,5–200 nm localize heterogeneously within the lens fiber
cell cytoplasm. Ab immunoreactivity was not detected at the plasmalemma. Boxed region denotes magnified area shown in Fig. 3k. Scale
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was also detected in homogenate of AD brain. The apparent Ab
monomer bands detected in DS and AD lens and brain homogenate
migrated with the same electrophoretic mobility observed in the
single band detected in a sample of purified synthetic human Ab40.
Ab monomer and apparent oligomeric species were also detected as
weak but distinct bands in normal control lens. Total Ab
immunoreactive material detected in the lens of a 2-year-old DS
subject was comparable to that detected in lenses from a 57-year-old
subject with familial AD and an 85-year-old subject with neuro-
pathologically-confirmed late-onset AD (Fig. 6C). The results of the
immunoblot analysis provide confirmatory evidence supporting the
finding of Ab in DS lenses and also demonstrate an apparent increase
in oligomeric Ab and corresponding decrease in monomeric Ab in
t h el e n sa saf u n c t i o no fa d v a n c i n ga g e .
Down Syndrome Ab Lens Pathology Recapitulated in a
Model Lens Protein System In Vitro
These data indicate that Ab accumulates in the cytoplasm of
supranuclear lens fiber cells in individuals with DS. We previously
showed that Ab binds (Kapp ,20 nmol/L) and co-aggregates with
aB-crystallin (HspB5) [28], a prototypic molecular chaperone and
small heat shock protein [32] that is abundantly present in the lens
bar=500 nm. (K) High-magnification electron micrograph of a single Ab-immunoreactive cytoplasmic protein aggregate (arrow) in a lens fiber cell
from same Down syndrome lens section shown in Fig. 3J. Multiple immunogold particles detect a single cytoplasmic protein aggregate with longest
axial cross-section ,50 nm. Scale bar=50 nm. (L) Confirmation of anti-Ab antibody specificity. Anti-Ab immunostaining was not detected in Down
syndrome lens when probed with immunodepleted anti-Ab antibody.
doi:10.1371/journal.pone.0010659.g003
Figure 4. Peptide sequencing of human Ab from Down syndrome lens. Tryptic digest tandem mass spectrometry sequencing of a ,4 kDa
HPLC eluate derived from human Down syndrome lens protein extract. The retention time of the immunopurified HPLC eluate used for sequencing
was identical to synthetic human Ab. The red shade box denotes the detected 12-residue internal tryptic peptide sequence 17LVFFAEDVGSNK28 that
uniquely identifies human Ab. We detected a second unique tryptic peptide 6HDSGYEVHHQK16 in another analysis (purple underline).
doi:10.1371/journal.pone.0010659.g004
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hypothesized that accumulation of amyloidogenic Ab peptides in
the lens fiber cell would potentiate cytosolic lens proteinaggregation
and increase Rayleigh light scattering. To investigate this
hypothesis, we incubated synthetic Ab with human lens protein
extract. Addition of Ab to human lens protein extract generated
birefringent congophilic aggregates consistent with amyloid
(Fig. 7A,B). Double immunogold electron microscopic analysis
revealed electron-dense aggregates that co-immunostained for Ab
and aB-crystallin (Fig. 7C). These hetero-oligomeric aggregates
demonstrated comparable size, morphology, and immunoreactivity
relative to the cytosolic protein aggregates identified in postmortem
DS lens specimens. Significantly, the dimensions of these Ab-
containing protein aggregates (,5pone.0010645 pone.0010646
200 nm in longest axial cross-section) describe classical Rayleigh
light scattering centers. Therefore, we sought to determine whether
Ab potentiated lens protein aggregation as assessed by quasi-elastic
light scattering (QLS) analysis. Addition of synthetic human Ab to
human lens protein extract resulted in dose- and time-dependent
increases in backscatterd light intensity that was not observed in
control lens protein extracts without added human Ab (Fig. 7D).
These findings are consistent with Ab-potentiated lens protein
aggregation.
Discussion
In this report, we identify the origin and pathogenic mechanism
of cataractogenesis in DS, establish the distinctive lens phenotype
in DS as a genetic cataract, and define the molecular
correspondence of DS-associated pathology in the lens and brain.
Taken together with our previous findings of supranuclear Ab lens
pathology in late-onset sporadic AD [28], these results also
establish the pathogenic relationship linking Ab pathology in the
lens and brain in both DS and AD.
AD neuropathology is an invariant feature of DS in subjects
over the age of 30 [18,19] but may emerge as early as the first
decade [18,34]. A critical factor contributing to the association of
DS and AD Ab pathology is the locus of the amyloid precursor
protein gene (APP, 21q21) on the long arm of chromosome 21
[16,35,36]. Chromosome 21 triplication leads to increased dosage
of the APP gene, accelerated cerebral Ab accumulation,
progressive AD neuropathology, and age-dependent cognitive
sequelae [18,37,38,39,40]. With the exception of a single reported
case of an individual with an atypical DS karyotype involving a
specific chromosome 21 micro-deletion in the APP gene locus [41],
all subjects with Down syndrome (including the rare cases
involving Robertsonian translocation, partial duplications, or
trisomic mosaicism) demonstrate triplication of the APP gene
locus (21q21), overexpress amyloid precursor protein (APP) in
affected somatic cells, accumulate b-amyloid peptides (Ab) in the
brain, and reveal evidence of early-onset Alzheimer’s disease (AD)
neuropathology [18,19,34,40,42].
In this report, we hypothesize and confirm that this genotype-
phenotype concordance extends to Ab-linked molecular pathol-
ogy in the supranucleus and deep cortex of the lens. The
characteristic cataract phenotype associated with Ab lens
pathology has been identified in only two clinical disorders,
Alzheimer’s disease [28] and as reported here, Down syndrome.
This distinctive supranuclear cataract phenotype has not been
reported in normal individuals, and is not observed in other non-
AD neurodegenerative diseases, nor in normal aged controls [28].
The classical cerulean ‘‘blue dot’’ cataracts characteristic of DS
initially emerge at the equatorial periphery of the lens, and over
time, encompass progressively larger areas of the supranucleus
and deep cortex (Fig. 8). While lens pathology observed in both
infantile and mature DS lenses reveal opaque regions that are
clinically described as supranuclear, the ages of the corresponding
fiber cells comprising these regions are different (Fig 8). In this
respect, it is important to note that the lens pathology in DS
lenses does not implicate involvement of lens fibers cells in the
fetal nucleus.
Distinctive lens pathology is recognized as a characteristic early-
onset ocular phenotype in subjects with DS that may be clinically
detectable early in life, and in some cases, at birth
[20,22,23,24,26,43,44]. By contrast, DS neuropathology and
cognitive sequelae typically emerge in the third decade of life
and age-dependently progress thereafter [18,19,37,38,39,40]. In
the present study, early-onset lens pathology is histochemically
documented in illustrative cases of two young adults (21 and 22
years of age) with DS. Lenses obtained from these donors revealed
marked Ab amyloid lens pathology that was evident not only in
the supranuclear subregion, but also throughout the anterior and
equatorial cortex and epithelium. Ab biochemical analysis of DS
and normal control lenses indicates that increased Ab expression
in the lenses of people with DS may be evident very early in life. In
one case included in this study, we detected abnormally high tissue
levels of Ab in the lens of a DS subject at 2 years of age. Although
visual impairment may not become clinically apparent due to the
peripheral distribution of these lenticular lesions relative to the iris,
it is certainly the case that Ab molecular pathology in the lens may
be amongst the earliest expressed age-dependent phenotypes in
Down syndrome.
Figure 5. Lens Ab extraction efficiency in sodium dodecyl
sulfate and formic acid. See text for details.
doi:10.1371/journal.pone.0010659.g005
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10659Figure 6. Increased Ab expression in Down syndrome lens and brain. (A-D) Anti-Ab ELISA analysis of human lens (A) and brain (B)
fractionated by Ab isoform. (A) Lens homogenates demonstrate elevated lens Ab in subjects with Down syndrome (n=8; p=0.027) compared to
normal controls (n=15). (B) Brain homogenates demonstrate elevated Ab in subjects with Down syndrome (n=8; p=0.007) and Alzheimer’s disease
(n=6; p=0.026) compared to normal controls (n=6). (C) Immunoblot analysis of Down syndrome lens and brain homogenates reveals an intense Ab-
immunoreactive band that migrated with an apparent molecular weight of ,4kDa corresponding to synthetic human Ab monomer (arrow). Note
strong band corresponding to Ab monomer in the 2-year-old Down syndrome lens (lane 7) and apparent shift from lower- to higher-order oligomeric
Ab in Down syndrome lenses with advancing age (lanes 7–9). Protein loading was normalized in each lane.
doi:10.1371/journal.pone.0010659.g006
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non-AD neurodegenerative diseases, nor in normal aged controls. In
this context, it is important to note that DS-associated cataracts are
phenotypically distinct from age-related cataracts (ARC) that
commonly emerge starting in the fifth decade of life and typically
localize in the central nuclear region. In contrastto the lens pathology
in ARC, the DS lens phenotype is often clinically detectable early in
life, and in some cases, may be present at birth
[20,22,23,24,26,43,44]. The distinctive lens phenotype associated
with DS is further distinguished from ARC by supranuclear Ab
histopathology, a pathological feature shared with late-onset AD [28].
The results of the present study support a DS-associated pathogenic
pathway linking progressive age-dependent Ab accumulation in the
lens and supranuclear cataractogenesis with corresponding cerebral
Ab accumulation and neuropathology in the brain. We propose the
following mechanistic pathway leading to expression of the charac-
teristic lens and brain phenotypes associated with DS (Fig. 9).
Increased APP gene dosage resulting from chromosome 21 triplication
(APP, 21q21) leads to increased expression of the amyloid precursor
protein (APP) and elevated levels of the pathogenic Ab cleavage
peptides in affected tissues. In the brain, Ab accumulation leads to
early-onset neuropathology and progressive age-dependent neurocog-
Figure 7. Ab potentiates lens protein aggregation and Rayleigh light scattering in vitro. (A) Brightfield photomicroscopic image of a
Congo red-stained protein aggregate (arrow) formed during incubation of human lens protein extract with synthetic human Ab.( B) Same Congo red-
stained lens protein aggregate demonstrating classical amyloid birefringence under cross-polarized illumination. (C) Anti-Ab/anti-aB-crystallin double
immunogold electron microscopic analysis of protein aggregates formed during incubation of human lens protein with synthetic human Ab. Larger
immunogold particles (15 nm diameter) detect Ab. Smaller immunogold particles (10 nm diameter) detect aB-crystallin. Box indicates region of detail
highlighted in Fig. 7D. Scale bar=200 nm. Inset, hetero-oligomeric composition noted in a single protein aggregate demonstrated by double
immunogold (anti-Ab and anti-aB-crystallin) electron microscopy. Analysis was performed on human lens protein incubated with synthetic human
Ab. Larger immunogold particles (15 nm diameter) detect Ab (black arrow). Smaller immunogold particles (10 nm diameter) detect aB-crystallin
(white arrow). Scale bar=50 nm. (D) Quasi-elastic light scattering (QLS) analysis detects increased backscattered light due to concentration-and time-
dependent protein aggregation during incubation of human lens protein with synthetic human Ab. Experimental samples studied by QLS were
analyzed by amyloid histochemistry (Fig. 7A,B) and double (anti-Ab and anti-aB-crystallin) immunogold electron microscopy (Fig. 7C).
doi:10.1371/journal.pone.0010659.g007
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supports the hypothesis that increased expression of Ab in the lens
leads to amyloidogenic interactions with other structural proteins (e.g.,
aB-crystallin) within the cytoplasm of supranuclear lens fiber cells.
This pathogenic cascade leads to increased lens protein aggregation,
light scattering, opacification, and ultimately, disease-linked cataracts
[45]. Given the fact that the long-lived lens fiber cells are metabolically
sluggish and demonstrate limited capacity to catabolize aggregated
protein, we speculate that DS-linked Ab amyloid pathology in the lens
may precede corresponding Ab pathology in the brain. Regardless,
the proposed pathogenic model for Ab pathology in both tissue
compartments (brain and lens) is in general agreement with a broad
conception of the amyloid cascade hypothesis [16,46,47].
We hypothesize that the Ab detected in DS lenses is generated
endogenously. The human lens expresses the full complement of
enzymes and precursor proteins necessary to generate and process Ab
[28,48,49,50]. In the present study, this hypothesis is supported by the
finding of intense Ab immunoreactivity in DS lens epithelial cells. Our
finding that lens fiber cell Ab is exclusively cytoplasmic suggests that
this amyloidogenic peptide may be released from intracellular
processing compartments during organelle disintegration accompa-
nying epithelial-to-fiber cell terminal differentiation. This model points
to the lens as an appropriate target for ascertaining the temporal origin
and natural history of AD-linked molecular pathology in vivo.
Our findings suggest an apparent temporal discordance in DS
with respect to phenotype expression in the lens and brain, with
pathology in the former preceding that in the latter. However, we
also observed variability in age-dependent phenotypic expression
of Ab molecular pathology in the lens that comports with
analogous variability in the brain of subjects with DS [34,51].
Figure 8. Age-dependent supranuclear cataractogenesis in Down syndrome. The anatomical localization of the characteristic Down
syndrome cataract phenotype (white shading) reflects the temporal origin and natural history of the underlying lens pathology. Fetal lens fiber cells
are not involved in this pathogenic process. Parentheses indicate equatorial axial extent of age-dependent disease-linked Abpathology in the
supranuclear subregion of Down syndrome lenses. See text for details.
doi:10.1371/journal.pone.0010659.g008
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PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e10659The significance and natural history of variability in Ab tissue
concentration in the lens and its possible relationship to the brain
in DS are subjects of ongoing investigation.
In this study, we identify Ab amyloid pathology as the shared
molecular etiology of two defining features of DS, namely,
supranuclear cataracts in the lens and AD neuropathology in the
brain. The proximal pathogenesis of both pathologies likely derives
from the primary chromosomal disorder and associated APP gene-
dosage imbalance (Fig. 9). The results reported here support a
testable pathogenic mechanism by which the primary chromosomal
disorder in DS may be translated into a distinctive phenotype
expressed in the lens. In this regard, the phenotypic concordance of
Ab lens pathology in both diseases, DS and AD, is striking. Given
that DS-linked pathology may be indicative of aberrant Ab
accumulation in both compartments, the lens may provide an
optically accessible target tissue for early detection and longitudinal
assessment of early Ab molecular pathology in DS and AD. Future
clinical studies will be required to systematically evaluate the
frequency of this supranuclear phenotype in DS patients. Quasi-
elastic light scattering instrumentation or other techniques may
provide a practical approach for quantitative assessment of specific
lens pathology throughout the course of the disease.
Supporting Information
Figure S1 Stereo image pair demonstrating mature supranucle-
ar pathology in the lens (with intact zonule fibers) from a subject
with Down syndrome. Characteristic circumferential supranuclear
cataract in the lens of a 64-year-old male subject with Down
syndrome. This distinctive cataract is evident as an annular half-
toroid band of opacification in the deep cortical and supranuclear
subregions of the lens (shown with intact zonules). This same lens
specimen is presented as a slit lamp image (Fig. 1H) and as a stereo
image pair (without zonules, Fig. 2A). This dramatic Down
syndrome cataract is phenotypically comparable to the subequa-
torial supranuclear cataract observed in advanced Alzheimer’s
disease. These distinctive supranuclear cataracts are not observed
in age-normal control subjects. See text for details.
Found at: doi:10.1371/journal.pone.0010659.s001 (2.77 MB TIF)
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